{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:19:55Z","timestamp":1788027595126,"version":"build-2784847793"},"reference-count":38,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,8,8]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness, treatment retention, and safety of secukinumab (SEC) uptitration to 300 mg in patients with axial spondyloarthritis (axSpA), including radiographic (r-axSpA) and nonradiographic (nr-axSpA) subtypes, with active disease despite receiving SEC 150 mg every 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, retrospective study included patients with axSpA who had received SEC 150 mg for \u2265 3 months and had active disease (Axial Spondyloarthritis Disease Activity Score [ASDAS] \u2265 2.1) at the time of dose escalation. Patients were followed for up to 24 months after escalation. Effectiveness was assessed through changes in ASDAS over time. Treatment retention was analyzed using Kaplan-Meier curves, with factors associated with discontinuation explored by Cox regression. Safety outcomes were reported as incidence of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 106 patients (77 r-axSpA, 29 nr-axSpA), ASDAS significantly declined within 6 months and was sustained through 24 months. Median ASDAS decreased from 4.1 to 2.0 in patients with r-axSpA and from 4.1 to 2.0 in those with nr-axSpA. Overall, 85.9% of patients achieved ASDAS \u2264 2.1 at least once after escalation. Retention of SEC 300 mg was 87.8% at 6 months and 59.1% at 24 months, with no significant difference between subtypes (log-rank\n                      <jats:italic>P<\/jats:italic>\n                      = 0.48). HLA-B27 positivity showed a nonsignificant trend toward higher discontinuation risk. AE incidence was 15.79 per 100 patient-years, and AEs were mostly mild infections and cutaneous reactions. No new safety signals were identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SEC uptitration to 300 mg was associated with sustained improvements in disease activity and favorable retention and safety in axSpA patients with active disease after receiving SEC 150 mg, supporting dose escalation as a clinically effective and safe strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0102","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:15:17Z","timestamp":1764598517000},"page":"1254-1262","source":"Crossref","is-referenced-by-count":3,"title":["Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-2778","authenticated-orcid":false,"given":"Dalifer","family":"Freites N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1820-9630","authenticated-orcid":false,"given":"Alicia Garc\u00eda","family":"Dorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garc\u00eda-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-5730","authenticated-orcid":false,"given":"Marta Valero","family":"Exp\u00f3sito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel De la Morena","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Arconada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Fern\u00e1ndez-Prada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"L\u00f3pez I G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio \u00c1lvarez","family":"de Cienfuegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"L\u00f3pez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-0341","authenticated-orcid":false,"given":"\u00c1lvaro Garc\u00eda","family":"Martos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025120106151113000_52.12.1254.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2025120106151113000_52.12.1254.2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10067-021-06008-8","article-title":"The disease burden of axial spondyloarthritis: through a gendered lens","volume":"41","author":"Khan","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025120106151113000_52.12.1254.3","first-page":"2142","article-title":"Axial spondyloarthritis: one year in review 2023","volume":"41","author":"Fattorini","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025120106151113000_52.12.1254.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket387"},{"key":"2025120106151113000_52.12.1254.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2025120106151113000_52.12.1254.6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00296-024-05601-9","article-title":"Axial spondyloarthritis: an overview of the disease","volume":"44","author":"Ivanova","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025120106151113000_52.12.1254.7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/14737167.2014.957679","article-title":"Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review","volume":"14","author":"Kotsis","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025120106151113000_52.12.1254.8","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen","year":"2006","journal-title":"J Rheumatol Suppl"},{"key":"2025120106151113000_52.12.1254.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.20990"},{"key":"2025120106151113000_52.12.1254.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025120106151113000_52.12.1254.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215707"},{"key":"2025120106151113000_52.12.1254.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225185"},{"key":"2025120106151113000_52.12.1254.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025120106151113000_52.12.1254.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2025120106151113000_52.12.1254.15","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/rheumatology\/kez171","article-title":"Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States","volume":"58","author":"Zhao","year":"2019","journal-title":"Rheumatology"},{"key":"2025120106151113000_52.12.1254.16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"2025120106151113000_52.12.1254.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087270"},{"key":"2025120106151113000_52.12.1254.18","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0356-9"},{"key":"2025120106151113000_52.12.1254.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.53"},{"key":"2025120106151113000_52.12.1254.20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nrrheum.2016.7","article-title":"Spondyloarthropathies: il-17A blockade ameliorates ankylosing spondylitis","volume":"12","author":"Duarte","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025120106151113000_52.12.1254.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"2025120106151113000_52.12.1254.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025120106151113000_52.12.1254.23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40744-021-00400-1","article-title":"Evidence for the use of secukinumab in patients with radiographic and non-radiographic axial spondyloarthritis in the last 5 years","volume":"9","author":"Aparicio","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025120106151113000_52.12.1254.24","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"},{"key":"2025120106151113000_52.12.1254.25","doi-asserted-by":"crossref","first-page":"1759720X211051471","DOI":"10.1177\/1759720X211051471","article-title":"Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025120106151113000_52.12.1254.26","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/rheumatology\/keae432","article-title":"A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment","volume":"64","author":"Deodhar","year":"2025","journal-title":"Rheumatology"},{"key":"2025120106151113000_52.12.1254.27","doi-asserted-by":"publisher","DOI":"10.4103\/sja.SJA_543_18"},{"key":"2025120106151113000_52.12.1254.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224434"},{"key":"2025120106151113000_52.12.1254.29","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/keaa422","article-title":"Non-radiographic versus radiographic axSpA: what\u2019s in a name?","volume":"59","author":"Michelena","year":"2020","journal-title":"Rheumatology"},{"key":"2025120106151113000_52.12.1254.30","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02613-9"},{"key":"2025120106151113000_52.12.1254.31","doi-asserted-by":"crossref","first-page":"610","DOI":"10.5414\/CP203927","article-title":"Comparative efficacy and safety of secukinumab 75 mg, 150 mg, and 300 mg in patients with active ankylosing spondylitis","volume":"59","author":"Song","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025120106151113000_52.12.1254.32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.11102","article-title":"Secukinumab 150\/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study","volume":"2","author":"Pavelka","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025120106151113000_52.12.1254.33","doi-asserted-by":"crossref","first-page":"1156557","DOI":"10.3389\/fmed.2023.1156557","article-title":"Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum","volume":"10","author":"Sivera","year":"2023","journal-title":"Front Med"},{"key":"2025120106151113000_52.12.1254.34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/jpm14040417","article-title":"Drug survival, effectiveness and safety of secukinumab in axial spondyloarthritis up to 4 years: a real-life single center experience","volume":"14","author":"Diaconu","year":"2024","journal-title":"J Pers Med"},{"key":"2025120106151113000_52.12.1254.35","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002802"},{"key":"2025120106151113000_52.12.1254.36","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220824"},{"key":"2025120106151113000_52.12.1254.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.11.003"},{"key":"2025120106151113000_52.12.1254.38","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003179"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:16:23Z","timestamp":1764598583000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.3899\/jrheum.2025-0102"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0102","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}